Holen Sie sich die Stockscreener-App
13.79
1.50%
-0.21
Handel nachbörslich:
13.82
0.03
+0.22%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt RDY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$14.00
Offen:
$13.74
24-Stunden-Volumen:
1.94M
Relative Volume:
0.99
Marktkapitalisierung:
$2.30B
Einnahmen:
$3.47B
Nettoeinkommen (Verlust:
$668.83M
KGV:
3.4366
EPS:
4.0127
Netto-Cashflow:
$253.46M
1W Leistung:
+0.88%
1M Leistung:
+2.53%
6M Leistung:
-9.73%
1J Leistung:
-6.85%
1-Tages-Spanne:
$13.70
$13.83
1-Wochen-Bereich:
$13.59
$14.02
52-Wochen-Spanne:
$12.26
$16.89
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Vergleichen Sie RDY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
13.79 | 2.30B | 3.47B | 668.83M | 253.46M | 4.0127 |
|
ZTS
Zoetis Inc
|
153.47 | 65.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 46.99B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.18 | 45.96B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
14.87 | 17.04B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
291.38 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Nomura | Buy → Neutral |
| 2024-01-11 | Herabstufung | Jefferies | Buy → Underperform |
| 2023-08-29 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-05-18 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-03-17 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-30 | Eingeleitet | JP Morgan | Underweight |
| 2022-11-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-01-03 | Fortgesetzt | BofA Securities | Neutral |
| 2021-07-27 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-02-02 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-09-18 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-09-18 | Hochstufung | Investec | Sell → Hold |
| 2020-01-28 | Herabstufung | CLSA | Buy → Outperform |
| 2020-01-27 | Herabstufung | CLSA | Buy → Outperform |
| 2020-01-09 | Hochstufung | Citigroup | Sell → Buy |
| 2019-11-04 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-09-04 | Hochstufung | Credit Suisse | Underperform → Outperform |
| 2019-07-01 | Hochstufung | Macquarie | Neutral → Outperform |
| 2019-06-20 | Eingeleitet | Deutsche Bank | Hold |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-02-19 | Hochstufung | CLSA | Outperform → Buy |
| 2019-01-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2017-09-21 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-08-31 | Hochstufung | CLSA | Underperform → Outperform |
| 2017-07-28 | Herabstufung | CLSA | Underperform → Sell |
| 2016-07-27 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2016-07-27 | Herabstufung | Jefferies | Hold → Underperform |
| 2016-02-10 | Hochstufung | Credit Agricole | Underperform → Buy |
| 2015-11-10 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Dr Reddys Laboratories Ltd Adr Aktie (RDY) Neueste Nachrichten
Dr. Reddy’s Laboratories Ltd. ADR (RDY) Performance and Fundamentals Dashboard tells a completely different story - Sete News
Asian ADRs See Mixed Results Despite Weekly Gains - Finimize
Dr. Reddy’s Looks Well Positioned for Long-Term Growth, Aided by Acquisitions and Partnerships - Morningstar
Investing in Dr. Reddy’s Laboratories Ltd. ADR (RDY): What You Must Know - knoxdaily.com
LLY Stock Quote Price and Forecast - CNN
NVO Stock Quote Price and Forecast - CNN
Zacks Industry Outlook Dr. Reddy's, Sandoz And Teva Pharmaceuticals - Barchart.com
Asian ADRs Climb, Showcasing North And South Asia Performances - Finimize
PDD Holdings Stock Delivers Phenomenal 5.82% Surge to $95.77 on April 14 – Bullish Momentum Lifts Chinese Tech - Hindustan Herald
3 Generic Drug Stocks To Watch Amid Trade War Jitters & Inflation Woes - Barchart.com
Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Acquired by Massachusetts Financial Services Co. MA - MarketBeat
Asian ADRs Shine As Zai Lab And CNFinance Lead The Gains - Finimize
Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading - TradingView
Mixed Performance For Asian Stocks Traded On US Markets - Finimize
Grantham Mayo Van Otterloo & Co. LLC Has $5.67 Million Position in Dr. Reddy's Laboratories Limited (NYSE:RDY) - MarketBeat
Asian Equities Traded in the US as American Depositary Receipts Tumble in Thursday Trading - TradingView
Pinpoint Asset Management Ltd Acquires 473,000 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY) - MarketBeat
Dr Reddy's Slapped Rs 2,395 Cr Income Tax Notice, Pharma Giant Denies Allegations - Medical Dialogues
Asian Equities Traded in the US as American Depositary Receipts Sharply Lower in Monday Trading - TradingView
Stocks to watch, April 7: IT, pharma, metals, oil-sensitive stocks, Nykaa, Dr Reddy's, Delhivery, Trent Ltd, and more - Upstox
Dr Reddy's gets over Rs 2,395 crore show cause notice from I-T authority - Moneycontrol
Asian Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading - TradingView
Asian Equities Traded in the US as American Depositary Receipts Trending Lower in Wednesday Trading - TradingView
Generics Industry: India Celebrates Pharmaceutical Tariffs Exemption but Uncertainty Remains High - Morningstar
US Tariffs on Pharma: Zydus, Dr Reddy’s at highest risk, says Jefferies; Check impact on other Indian pharma stocks - Mint
Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Acquired by GQG Partners LLC - MarketBeat
American Healthcare REIT Inc (AHR) Stock: A Year of Decreases and Increases - The InvestChronicle
Asian Equities Traded in the US as ADRs Rise in Tuesday Trading - MSN
Asian Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - TradingView
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Asian Equities Traded in the US as American Depositary Receipts Lower in Friday Trading - TradingView
Infosys, Wipro, TCS, other IT stocks fall up to 3% after Accenture Q2 results. Details here - Mint
Infosys, Wipro ADRs drop over 3% on NYSE after Accenture hikes full-year revenue guidance to 5-7% on AI boom - Mint
Asian Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - TradingView
Asian Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading - TradingView
Asian Equities Traded in the US as American Depositary Receipts Track Sharply Lower in Tuesday Trading - TradingView
FDA accepts Dr. Reddy’s biosimilar application for bone drugs By Investing.com - Investing.com India
Asian Equities Traded in the US as American Depositary Receipts Open Week Sharply Higher - TradingView
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.
Asian Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading - TradingView
Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading - TradingView
Asian Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading - TradingView
Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up 1.5% for Week - TradingView
Is TG Therapeutics Inc (NASDAQ: TGTX) A Good Investment For New Investors Now? - Stocks Register
Senores Pharmaceuticals to acquire 14 ANDAs from Dr Reddy's - Business Standard
Rhumbline Advisers Grows Position in Dr. Reddy's Laboratories Limited (NYSE:RDY) - MarketBeat
Dr. Reddy's Laboratories Ltd. Sponsored ADR to Host Earnings Call - ACCESS Newswire
Stocks to watch: Bharti Airtel, Wipro, Coforge, Dr Reddy’s, Vakrangee among shares to remain in focus today - Mint
Finanzdaten der Dr Reddys Laboratories Ltd Adr-Aktie (RDY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
1.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):